Vincerx Pharma (VINC) announced plans to implement cost-controls and explore strategic alternatives to support advancing the Phase 1 study of VIP943, the company’s novel CD123-targeted antibody-drug ...
“Vincerx is a young company poised to deliver paradigm-shifting therapeutics to address the unmet medical needs of cancer patients worldwide,” said Ahmed Hamdy, CEO and cofounder of Vincerx.
“We believe VIP943 is a highly differentiated and valuable asset, and we remain fully committed to advancing this program,” said Ahmed Hamdy, M.D., Chief Executive Officer. “As we shared in October, ...
Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting ...